The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin‐1 Mediated Autoinflammatory Diseases: Cryopyrin‐Associated Periodic Syndromes, Tumour Necrosis Factor Receptor‐Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin‐1 Receptor Antagonist
Year: 2022
Type: review
Abstract: BACKGROUND: The interleukin-1 (IL-1) mediated systemic autoinflammatory diseases, including the cryopyrin- associated periodic syndromes (CAPS), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD) and deficiency of the IL-1 receptor antagonist (DIRA), belong to a group of rare immunodysregulatory diseases that primarily present in early childhood with variable multiorgan involvement. When untreated, patients with severe clinical phenotypes have a poor prognosis, and diagnosis and management of these patients can be challenging. However, approved treatments targeting the proinflammatory cytokine IL-1 have been life changing and have significantly improved patient outcomes. OBJECTIVE: To establish evidence-based recommendations for diagnosis, treatment and monitoring of patients with IL-1 mediated autoinflammatory diseases to standardise their management. METHODS: A multinational, multidisciplinary task force consisting of physician experts, including rheumatologists, patients or caregivers and allied healthcare professionals, was established. Evidence synthesis, including systematic literature review and expert consensus (Delphi) via surveys, was conducted. Consensus methodology was used to formulate and vote on statements to guide optimal patient care. RESULTS: The task force devised five overarching principles, 14 statements related to diagnosis, 10 on therapy, and nine focused on long-term monitoring that were evidence and/or consensus-based for patients with IL-1 mediated diseases. An outline was developed for disease-specific monitoring of inflammation-induced organ damage progression and reported treatments of CAPS, TRAPS, MKD and DIRA. CONCLUSION: The 2021 EULAR/American College of Rheumatology points to consider represent state-of-the-art knowledge based on published data and expert opinion to guide diagnostic evaluation, treatment and monitoring of patients with CAPS, TRAPS, MKD and DIRA, and to standardise and improve care, quality of life and disease outcomes.
Source: Arthritis & Rheumatology
DOI: 10.1002/art.42139
Authors: Micol Romano, Z. Serap Arici, David Piskin, Sara Alehashemi, Daniel Aletaha, Karyl Barron, Susanne Benseler, Roberta A. Berard, Lori Broderick, Fatma Dedeoglu, Michelle Diebold, Karen Durrant, Polly Ferguson, Dirk Foell, Jonathan S. Hausmann, Olcay Y. Jones, Daniel Kastner, Helen J. Lachmann, Ronald M. Laxer, Dorelia Rivera, Nicolino Ruperto, Anna Simon, Marinka Twilt, Joost Frenkel, Hal M. Hoffman, Adriana A. de Jesus, Jasmin B. Kuemmerle‐Deschner, Seza Ozen, Marco Gattorno, Raphaela Goldbach‐Mansky, Erkan Demirkaya
Institutions: Western University, Şanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesi, National Institute of Allergy and Infectious Diseases, Medical University of Vienna, National Institutes of Health, University of Calgary, University of California San Diego, Rady Children's Hospital-San Diego, Harvard University, University of Iowa, University of Münster, Boston Children's Hospital, Beth Israel Deaconess Medical Center, Walter Reed National Military Medical Center, National Human Genome Research Institute, University College London, University of Toronto, Hospital for Sick Children, Istituto Giannina Gaslini, Radboud University Medical Center, Wilhelmina Children's Hospital, Hacettepe University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4281720102
